Shire Canada Inc. ("Shire Canada") and Shire Human Genetic Therapies (Canada) Inc. ("Shire Human Genetic Therapies (Canada)") are wholly owned subsidiaries of Shire plc, a global specialty biopharmaceutical company that works closely with specialist physicians to develop and market medicines that improve the quality of life for patients, their families and caregivers.

Shire focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies, hereditary angioedema, as well as gastrointestinal and renal diseases.

In Canada, Shire is a proud member of Canada's Research-Based Pharmaceutical Companies (Rx&D) and of BIOTECanada.

Our Canadian offices are located in the Greater Montreal area, in Québec:

2250 Alfred-Nobel Blvd, Suite 500
Saint-Laurent, QC H4S 2C9
Tel: +1 514 787 2300
Fax: +1 514 787 2427

Site Image